Clinical Trial Detail

NCT ID NCT02066532
Title Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Kevin Kalinsky
Indications

Her2-receptor positive breast cancer

Therapies

Ruxolitinib + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST